Literature DB >> 18835834

Impact of AB0-blood group incompatibility on the outcome of recipients of bone marrow transplants from unrelated donors in the Japan Marrow Donor Program.

Fumihiko Kimura1, Ken Sato, Shinichi Kobayashi, Takashi Ikeda, Hiroshi Sao, Shinichiro Okamoto, Koichi Miyamura, Shinichiro Mori, Hideki Akiyama, Makoto Hirokawa, Hitoshi Ohto, Hiroshi Ashida, Kazuo Motoyoshi.   

Abstract

BACKGROUND: Although the AB0 blood group is one of two major antigen systems of relevance for transplantation in humans, there are still conflicting data concerning the influence of AB0 incompatibility on transplant outcome. This study investigated the effect of AB0 incompatibility in recipients of bone marrow transplants from unrelated donors. DESIGN AND METHODS: We retrospectively analyzed data from 5,549 patients who underwent bone marrow transplantation from unrelated donors in the Japan Marrow Donor Program.
RESULTS: Overall survival rates in the group with major and minor mismatches were significantly lower than the rate in the AB0-identical group (AB0-identical 63.0%; major mismatch, 56.9%; minor mismatch, 57.1% at 1 year). Treatment-related mortality was higher in the major and minor mismatch groups, but there was no significant difference in the rate of relapse. Cox proportional hazards modeling showed that both major and minor AB0 incompatibility were significant risk factors for transplant-related mortality, independently of disease, patients' age, and HLA incompatibility. Delayed engraftment of neutrophils, platelets, and erythrocytes was observed in transplants with major incompatibility. There was a high incidence of grade 3 and 4 acute graft-versus-host disease in the groups with major and minor mismatches, which was caused by a high incidence of stage 2 to 4 liver graft-versus-host disease. Interestingly, the risk of grade 2 to 4 graft-versus-host disease in the major mismatch group was higher in patients with early engraftment of erythrocytes. Among the patients receiving reduced-intensity conditioning, the transplant-related mortality was also increased in AB0-incompatible transplants.
CONCLUSIONS: Major and minor AB0 incompatibility have specific effects on transplant-related mortality and acute graft-versus-host disease in recipients of bone marrow transplants from unrelated donors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18835834     DOI: 10.3324/haematol.12933

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  24 in total

1.  ABO, alemtuzumab and allogeneic transplantation.

Authors:  L Cooling
Journal:  Bone Marrow Transplant       Date:  2015-04-20       Impact factor: 5.483

2.  Fully automated, clinical-grade bone marrow processing: a single-centre experience.

Authors:  Benedetta Mazzanti; Serena Urbani; Simone Dal Pozzo; Paola Bufano; Lara Ballerini; Alessia Gelli; Irene Sodi; Irene Donnini; Massimo Di Gioia; Stefano Guidi; Julien Camisani; Riccardo Saccardi
Journal:  Blood Transfus       Date:  2016-09-27       Impact factor: 3.443

3.  Major ABO incompatible BMT in children: determining what residual volume of donor red cells can safely be infused following red cell depletion.

Authors:  K Patrick; W Lau; A Gassas; E McDougall; J Doyle; M Ali; J Krueger; S Courtney; C Armstrong; R M Egeler; T Schechter
Journal:  Bone Marrow Transplant       Date:  2015-01-26       Impact factor: 5.483

4.  Impact of ABO blood group mismatch in alemtuzumab-based reduced-intensity conditioned haematopoietic SCT.

Authors:  C K Brierley; T J Littlewood; A J Peniket; R Gregg; J Ward; A Clark; A Parker; R Malladi; P Medd
Journal:  Bone Marrow Transplant       Date:  2015-04-13       Impact factor: 5.483

5.  Persistence of recipient-type endothelium after allogeneic hematopoietic stem cell transplantation.

Authors:  Regula J Mueller; Georg Stussi; Gisella Puga Yung; Milica Nikolic; Davide Soldini; Jörg Halter; Sandrine Meyer-Monard; Alois Gratwohl; Jakob R Passweg; Bernhard Odermatt; Urs Schanz; Barbara C Biedermann; Jörg D Seebach
Journal:  Haematologica       Date:  2010-10-07       Impact factor: 9.941

6.  ABO mismatch is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation.

Authors:  Aaron C Logan; Zhiyu Wang; Kamran Alimoghaddam; Ruby M Wong; Tze Lai; Robert S Negrin; Carl Grumet; Brent R Logan; Mei-Jie Zhang; Stephen R Spellman; Stephanie J Lee; David B Miklos
Journal:  Biol Blood Marrow Transplant       Date:  2015-01-05       Impact factor: 5.742

Review 7.  ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Nina Worel
Journal:  Transfus Med Hemother       Date:  2015-10-29       Impact factor: 3.747

8.  The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy.

Authors:  Craig Kollman; Stephen R Spellman; Mei-Jie Zhang; Anna Hassebroek; Claudio Anasetti; Joseph H Antin; Richard E Champlin; Dennis L Confer; John F DiPersio; Marcelo Fernandez-Viña; Robert J Hartzman; Mary M Horowitz; Carolyn K Hurley; Chatchada Karanes; Martin Maiers; Carlheinz R Mueller; Miguel-Angel Perales; Michelle Setterholm; Ann E Woolfrey; Neng Yu; Mary Eapen
Journal:  Blood       Date:  2015-11-02       Impact factor: 22.113

9.  IgM anti-recipient ABO antibodies predict acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.

Authors:  Yoshitaka Zaimoku; Akiyoshi Takami; Hidehiro Sato; Maki Utsumi; Shinji Nakao
Journal:  Int J Hematol       Date:  2013-05-10       Impact factor: 2.490

10.  NKG2D gene polymorphism has a significant impact on transplant outcomes after HLA-fully-matched unrelated bone marrow transplantation for standard risk hematologic malignancies.

Authors:  J Luis Espinoza; Akiyoshi Takami; Makoto Onizuka; Hiroshi Sao; Hideki Akiyama; Koichi Miyamura; Shinichiro Okamoto; Masami Inoue; Yoshinobu Kanda; Shigeki Ohtake; Takahiro Fukuda; Yasuo Morishima; Yoshihisa Kodera; Shinji Nakao
Journal:  Haematologica       Date:  2009-10       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.